Correlation between mean arterial pressure (MAP) and length of stay (LoS) of heart failure in-patients with sacubitril/valsartan and ramipril at X Hospital Semarang
Abstract
Heart failure is a health problem with high morbidity and mortality rates globally and nationally, so optimal therapy is needed to improve clinical outcomes and efficiency. Sacubitril/valsartan (angiotensin receptor neprilysin inhibitor/ARNI) and ramipril (ACE inhibitor/ACEi) have become the therapeutic options in heart
failure patients. However, the effectiveness of both therapies on length of stay (LoS) and changes in mean arterial pressure (MAP) in the Indonesian population has not much studied. This study used an observational retrospective design on the medical record data of heart failure inpatients at X Hospital, Semarang,
during January to December 2024 period. All in-patients who received sacubitril/valsartan or ramipril therapy (in combination with beta blockers and aldosterone receptor antagonists) were included, and were differentiated based on changes in MAP (up, down and constant). Correlation statistical analysis was performed
with normality test, Kruskal-Wallis, and Anova tests to correlate the LoS and MAP changes between therapy. A total of 131 patients were categorized by therapy and MAP changes. The average LoS on Sacubitril/valsartan and Ramipril therapy was approximately 5–6 d each for the entire MAP change group. Statistical tests
showed no significant difference between the two therapies for LOS, as well as of MAP changes (p > 0.05). MAP changes (up, down, constant) in heart failure in-patients treated with sacubitril/valsartan and ramipril provided variation in LoS, but the differences were not statistically significant between the two therapies.
References
Hussein WF. The pathophysiology of heart failure: A review article. Indones J Health Sci Med, 2024;1(1). https://doi.org/10.21070/ijhsm.v2i1.82
Shams P, Malik A, Chhabra L. Heart failure (congestive heart failure). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Jan 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK430873/
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation [Internet]. 2017. [cited 2025 Dec 12];136(6).
Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000509
Gao Q, Lin Y, Xu R, Zhang Y, Luo F, Chen R, et al. Association between mean arterial pressure and clinical outcomes among patients with heart failure. ESC Heart Fail. 2023;10(4):2362–74. https://doi.org/10.1002/ehf2.14401.
Hermawan IKH, Kawilarang KC, Hartono F. Clinical characteristics and profile of heart failure patients at dr. Ramelan Navy Hospital in 2020. CCJ, 2022; 3(1):9–14. https://doi.org/10.20473/ccj.v3i1.2022.9-14
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, 2019; 381(17):1609–20. https:/doi.org/10.1056/NEJMoa1908655
Ma H, Li H, Sheng S, Quan L, Yang Z, Xu F, et al. Mean arterial pressure and mortality in patients with heart failure: a retrospective analysis of Zigong heart failure database. Blood Press Monit, 2023; 28(6):343–50.
https://doi.org/10.1097/MBP.0000000000000674
Oguntade AS, Ogah OS, Adebiyi AA, Aje A. Systolic blood pressure, mean arterial pressure and incident mortality in heart failure in a West-African cohort: the blood pressure paradox revisited. Egypt J Intern Med, 2024;36(1):112. https://doi.org/10.1186/s43162-024-00378-6
Chen DY, Chen CC, Tseng CN, Chen SW, Chang SH, Huang WK, et al. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study. eClinicalMedicine, 2021;41:101149.
https://doi.org/10.1016/j.eclinm.2021.101149.
Evbayekha E, Idowu AB, LaRue S. Sacubitril/valsartan vs ACE inhibitors or ARBs. JACC Adv, 2025;4(3):101598. https://doi.org/10.1016/j.jacadv.2025.101598.
Purwowiyoto SL, Angelia F, Prawara AS. Sacubitril/valsartan: the role of neprilysin pathway in heart failure. Indones J Clin Pharm, 2021;10(2):133-43. https://doi.org/ 10.15416/ijcp.2021.10.2.133
Yamazaki T. Enhancing home blood pressure management: implementation of the sacubitril/valsartan treatment in practical clinical settings. JMA J, 2025;8(2): 479-85. https://doi.org/10.31662/jmaj.2024-0262.
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, et al. Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol, 2022;7(1):17-25. https://doi.org/ 10.1001/jamacardio.2021.4567.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI Trial. Circulation, 2022;145(1):87–9.
https://doi.org/ 10.1161/CIRCULATIONAHA.121.057429.
Ráduly AP, Saman Kothalawala E, Balogh L, Majoros Z, Pólik Z, Fülöp L, et al. Sacubitril/valsartan improves hemodynamic parameters of pulmonary and systemic circulation in patients awaiting heart transplantation. J Clin Med, 2025;14(8):2539. https://doi.org/10.3390/jcm14082539
Triposkiadis F, Sarafidis P, Briasoulis A, Magouliotis DE, Athanasiou T, Skoularigis J, et al. Hypertensive heart failure. J Clin Med, 2023;12(15):5090. https://doi.org/ 10.3390/jcm12155090.
PERKI. Pedoman tatalaksana gagal jantung (2nd ed.). Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2020.
Chimura M, Butt JH, Matsumoto S, McMurray EGM, Henderson AD, Talebi A, et al. Comprehensive analysis of the effects of sacubitril/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM‐HF. J Am Heart Assoc, 2025;14(9):e038249. https://doi.org/10.1161/JAHA.124.038249
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077
Andre N, Adila L, Rizka A, Rusdi L. Efektivitas sacubitril/valsartan dalam mencegah gagal jantung pada STEMI pasca percutaneous coronary intervention. J Penyakit Dalam Indones, 2023;10(4): 215-22. https://doi.org/10.7454/jpdi.v10i4.1435
Lim AH, Rahim NA, Zhao J, Cheung SYA, Lin Y. Cost effectiveness analyses of pharmacological treatments in heart failure. Front Pharmacol, 2022;13. 919974. https//doi.org/10.3389/fphar.2022.919974.
Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin inhibitors in heart failure. JACC Basic Transl Sci, 2023;8(1):88–105. https://doi.org/ 10.1016/j.jacbts.2022.05.010.
Marulin D, Zakiyah N, Puspitasari IM, Rahayu C. Analisis efektivitas biaya penggunaan sacubitril/valsartan dibandingkan ramipril pada pasien gagal jantung dengan hipertensi di RSUP dr. Hasan Sadikin Bandung. Indones J Clin Pharm, 2025;12(2):86–97. https://doi.org/10.15416/ijcp
Burstein B, Tabi M, Barsness GW, Bell MR, Kashani K, Jentzer JC. Association between mean arterial pressure during the first 24 hours and hospital mortality in patients with cardiogenic shock. Crit Care, 2020;24(1):513. https://doi.org/10.1186/s13054-020-03217-6
Zakiyah N, Sinuraya RK, Kusuma AS, Suwantika AA, Lestari K. Cost-effectiveness analysis of sacubitril/valsartan compared to enalapril for heart failure patients in Indonesia. Clin Outcomes Res, 2021;13:863–72. https://doi.org/ 10.2147/CEOR.S322740.
Montalto M, D’Ignazio F, Camilli S, Di Francesco S, Fedele M, Landi F, et al. Heart failure in older patients: An update. J Clin Med, 2025;14(6):1982. https://doi.org/ 10.3390/jcm14061982.
Nadia R. Karakteristik pasien gagal jantung yang dirawat inap di RSUD Provinsi NTB periode Januari-Desember, 2020. [Skripsi]. Mataram: Universitas Mataram; 2025 [cited 2026 Jan 2]. Available from: https://eprints.unram.ac.id/48426/
Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 2023; 82(1):1–12. https://doi.org/ 10.1016/j.jacc.2023.04.019
Patel P, Nicolas D, Reed M. Sacubitril-valsartan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Jan 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507904/
